The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical ImplicationsRNA在多发性骨髓瘤生物学中的意义及其临床意义

发表日期：2021-11-19

mRNA在多发性骨髓瘤生物学中的意义及其临床意义

Multiple myeloma (MM) is a genetically complex disease that results from a multistep transformation of normal to malignant plasma cells in the bone marrow. However, the molecular mechanisms responsible for the initiation and heterogeneous evolution of MM remain largely unknown. A fundamental step needed to understand the oncogenesis of MM and its response to therapy is the identification of driver mutations. The introduction of gene expression profiling (GEP) in MM is an important step in elucidating the molecular heterogeneity of MM and its clinical relevance. Since some mutations in myeloma occur in non-coding regions, studies based on the analysis of mRNA provide more comprehensive information on the oncogenic pathways and mechanisms relevant to MM biology. In this review, we discuss the role of gene expression profiling in understanding the biology of multiple myeloma together with the clinical manifestation of the disease, as well as its impact on treatment decisions and future directions.

多发性骨髓瘤 (MM) 是一种遗传复杂的疾病，由骨髓中正常浆细胞向恶性浆细胞的多步转化引起。然而，负责 MM 的起始和异质进化的分子机制在很大程度上仍然未知。了解 MM 的发生及其对治疗的反应所需的一个基本步骤是识别驱动突变。在 MM 中引入基因表达谱 (GEP) 是阐明 MM 的分子异质性及其临床相关性的重要一步。由于骨髓瘤的一些突变发生在非编码区，基于 mRNA 分析的研究提供了关于与 MM 生物学相关的致癌途径和机制的更全面的信息。

40层细胞工厂

Gene expression profiling studies provide important information regarding the biology of multiple myeloma and may serve as a tool to predict outcomes and guide therapy. In the era of personalized medicine, the future lies in enabling therapy to be chosen based on the presence of specific mutations and gene expression profiles. However, the complexity of the MM genome and transcriptome still requires further investigation.
在回顾信使 RNA 在多发性骨髓瘤生物学中的作用时，重要的是包括嵌合抗原受体 (CAR) T 细胞疗法领域的最新成果。尽管引入了许多新的治疗策略，但多发性骨髓瘤仍然无法治愈，需要持续干预以控制疾病。然而，最近的一个有希望的发展是设计了一种工程化的 T 细胞产品 Descartes-08，它用抗 B 细胞成熟抗原 (BCMA) CAR mRNA 瞬时修饰自体 CD8 + T 细胞的纯化群体，如报道林等人。

A.P. wrote the paper. A.P., P.R., T.R. and D.M. examined the available data, reviewed, and revised the manuscript and provided their approval of the final version of the manuscript. All authors agree to be accountable for all aspects of the work. All authors have read and agreed to the published version of the manuscript.
Descartes-08 是通过 mRNA 转染设计的，可以在规定的时间内表达抗 BCMA CAR。mRNA 是通过线性化 DNA 质粒的体外转录合成的 [ 78]。这种无病毒 CAR-T 细胞技术的发展最近导致了第一次临床试验的启动。